The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown. Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/ ®lopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase).
The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown. Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/ ®lopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase).
Since the process of cell migration must involve changes in adhesion, we explored the potential HRG regulation of paxillin, a major cytoskeletal phosphoprotein of focal adhesion. We report that HRG stimulation of noninvasive breast cancer cells resulted in stimulation of p38 mitogen-activated protein kinase (p38 MAPK ), extracellular signal-regulated kinases (ERK) and PI-3K, and a concurrent unexpected increase in the level of paxillin phosphorylation on serine residue which was sensitive to protein-phosphatase 2b but not to protein tyrosine phosphatase 1. In addition, HRG triggered a rapid redistribution of paxillin to the perinuclear regions from the tyrosine-phosphorylated focal adhesions, and increased cell scattering. There was no eect of HRG on the state of phosphorylation and localization of focal adhesion kinase. The HRG-induced increase in serine phosphorylation of paxillin and cell scattering were selectively inhibited by a speci®c inhibitor of p38 MAPK or a dominant-negative p38 MAPK mutant, but not by inhibitors of p42/44 MAPK or PI-3 kinase pathways. For the ®rst time our results have shown that HRG, a potent migratory growth factor stimulates serine phosphorylation of paxillin. These ®ndings suggest a role of p38
MAPK Introduction
Abnormalities in the expression, structure, or activity of proto-oncogene products contribute to the development and maintenance of the malignant phenotype. For example, HER2 (also known as c-erbB2 or c-neu) encodes a 185 kD transmembrane glycoprotein with intrinsic tyrosine kinase activity (Stern et al., 1986 ) that has been shown to be overexpressed or ampli®ed, or both, in a number of human malignancies, including breast cancer (Slamon et al., 1987) . Overexpression of the HER2 receptor is associated with increased progression and metastasis, an aggressive clinical course, and decreased disease-free survival in human breast cancer patients (Slamon et al., 1989) . Recently, two additional members, HER3 and HER4, have been added to the human EGF receptor (HER) family. All of these receptors share sequence homology with the tyrosine kinase domain of HER1 (Alroy and Yarden, 1997; Hynes and Stern, 1994) . The regulation of HER family members is complex as they can be transactivated by heterodimeric interaction between two HER members, and thus, can utilize multiple pathways to execute their biological functions (Alroy and Yarden, 1997; Hynes and Stern, 1994) . For example, HER3 and HER4 receptors bind to more than a dozen isoforms of the heregulins (HRGs) (Peles et al., 1992) , and can activate the HER2 receptor as a result of HER2/HER3 or HER2/HER4 heterodimer interactions. A ligand that interacts with HER2 in the absence of other HER family members has yet to be identi®ed. It is believed that among the HER family, the HER2/HER3 dimer complex elicits the most potent mitogenic signal (Alroy and Yarden, 1997) . In addition to HER2 overexpression, accumulating evidence suggests that the HRG pathway may be involved in the progression of breast cancer cells to a more invasive phenotype (Benz et al,. 1993; Kumar et al., 1995; Adam et al., 1998) . HRG stimulation of breast cancer cells enhances Shc phosphorylation and its association with phosphorylated HER3 (Kim et al., 1994) , activation of PI 3-kinase Adam et al., 1998) , and activation of MAP-kinases and JNKkinases (Pinkas-Kramarski et al., 1997; Marte et al., 1995) . In spite of the widely acknowledged role of HER2 in breast cancer, the mechanism through which HRG participates in breast cancer progression remains elusive.
The exposure of cells to growth factors has been shown to cause cytoskeleton reorganization, formation of lamellipodia, membrane ruing and altered cell morphology, and accordingly, has been implicated in stimulating cell migration and invasion (Hall, 1998; Mitchison and Cramer, 1996) . The leading edge of a motile cell is composed of thin protrusions of membrane that continuously extend and retract, mediating the initial stage of cell movement and determining the direction of advance. The cell migration also involves changes in cytoskeleton actin stress-®bers that end in focal adhesion, points of attachment of the plasma membrane to the substratum. The focal adhesion points play an important role in the regulation of cell motility, as it involves cycles of formation of cell adhesion and cell spreading by disassembling the components of cell adhesion (Burridge et al., 1997) . Increased cell spreading contributes to an increased cell migration. Growth factor(s) stimulation of cells is accompanied by a rapid increase in tyrosine phosphorylation of focal adhesion proteins, most notably, FAK, paxillin and talin. The activation of focal adhesion complexes, in turn, initiates a cascade of interactions with other proteins containing SH2/SH3 domains (such as vSrc, vCrk and vinculin) and/or with the components of Ras signaling (such as Grb2 and Sos) (Bergman et al., 1995; Schlaepfer et al., 1994; Weiner et al., 1993) . In most cell types, tyrosine phosphorylation of FAK coincides with the tyrosine phosphorylation and association with a 66 kD protein (presumably paxillin) and these proteins co-localize in focal adhesions (Rankin and Rozengurt, 1994; Turner et al., 1995) . Since paxillin has been shown to be phosphorylated in vitro by FAK (Turner et al., 1993; Bellis et al., 1995) , it is believed to be a major substrate for FAK. Recently, both paxillin and FAK have been shown to be phosphorylated on tyrosine residues by a number of growth factors, including PDGF (Abedi et al., 1995) , VEGF (Abedi and Zachary, 1997) , IGF-1 (Leventhal et al., 1997) , HGF (Matsumoto et al., 1994) , and Stem cell factor (Hiregowdara et al., 1997) . Accordingly, tyrosine phosphorylation of paxillin by growth factors has been implicated in the regulation of cell spreading and motility.
Growth factors play an essential role in the regulation of proliferation of mammary epithelial cells. Recently, HRG has been shown to be involved in morphogenesis and ductal migration in mammary epithelium (Yang et al., 1995; Jones et al., 1996) and also in the formation of lamellipodia/®lopodia, increased cell migration and invasiveness of breast cancer cells . Since the process of cell migration must involve modulation in adhesion, we investigated the potential role of paxillin, a major component of focal adhesion, in HRG-induced alterations in cytoskeleton system. We report that HRG stimulation of non-invasive breast cancer MCF-7 cells resulted in an unexpected stimulation of serine phosphorylation of paxillin, a rapid redistribution of paxillin to the perinuclear regions from the tyrosinephosphorylated focal adhesions, and concurrent changes in cell shape and scattering. The HRGinduced increase in paxillin serine phosphorylation and scattering were inhibited by a speci®c inhibitor of p38 MAPK , SB203580, or a dominant-negative p38 MAPK mutant, but not by inhibitors of extracellular signalregulated kinases or PI-3 kinase. These ®ndings suggest a role of p38 MAPK signaling in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape changes and cell scattering.
Results

HRG induces serine phosphorylation of paxillin in MCF-7 breast cancer cells
Recently we have demonstrated that HRG-b1 (HRG) is a very potent cell migratory growth factor to MCF-7 breast cancer cells Vadlamudi et al., 1999) . HRG treatment induces motile phenotype, cell spreading and scattering in MCF-7 breast cancer cells. This phenotype was independent of the nature of extracellular matrix, including collagen I and collagen IV (Figure 1 ), and ®bronectin (data not shown). In the present study, we set out to delineate the role(s) of paxillin, a major component of focal adhesion, in HRG-induced remodeling of the cytoskeleton system. Results in Figure 2A demonstrate that treatment of MCF-7 cells with HRG was accompanied by the development of an electrophoretically slower migrating modi®ed form of paxillin in a time-dependent manner, as determined by band-shift analysis using immunoblotting with an anti-Paxillin mAb. The appearance of the slower migrating form of paxillin was at the expense of the faster migrating form, and this eect was maximum between 30 ± 60 min after HRG treatment. As an internal control, the upper portion of the same blot was immunoblotted with an anti-FAK Ab, and there was no eect of HRG (1 nM) on its mobility. In addition, a direct immunoprecipitation with anti-FAK mAb in ®ve separate experiments also did not detect any eect of HRG (1 nM) on FAK tyrosine phosphorylation and two representative blots of FAK immunoprecipitations are shown in Figure 2B ,C. In addition, immunoprecipitation of paxillin and blotting with anti-phosphotyrosine PY20 antibody revealed detectable steady state levels of basal tyrosine phosphorylation of paxillin but there was no signi®cant eect of HRG on the level of tyrosine phosphorylation of paxillin compared to control cells ( Figure 2B ). To determine whether the observed eect of HRG on the mobility shift of paxillin was not restricted to the HRG concentration used, cells were also treated with lower HRG dose (0.1 nM) and status of paxillin mobility shift and tyrosine phosphorylation was analysed ( Figure 2D ). Lower concentration of HRG also resulted in stimulation of mobility shift of paxillin (presumably due to serine phosphorylation). A modest but less signi®cant increase in tyrosine phosphorylation of paxillin was also observed between 15 ± 30 min of HRG treatment. Since other polypeptide factors are known to modify paxillin by stimulating its tyrosine phosphorylation (Abedi et al., 1995; Abedi and Zachary, 1997; Leventhal et al., 1997; Matsumoto et al., 1994; Hiregowdara et al., 1997) , we examined the eect of HRG on stimulation of phosphorylation of paxillin labeled in vivo. MCF-7 cells were equilibrium labeled with 32 P-orthophosphoric acid, incubated for 30 min with HRG before lysis, and immunoprecipitated with anti-Paxillin-or anti-phosphotyrosine PY20 mAbs. As shown in Figure 3A , there was a sixfold increase in the levels of HRG-induced phosphorylation of paxillin (compare lane 2 with lane 1). Surprisingly, immunoprecipitation with PY20 antibody which recognized tyrosine phosphorylated proteins in lysates from HRGstimulated cells, but failed to precipitate any detectable 32 P-labeled phospho protein in the range of 60 ± 70 kD (compare lane 4 with lane 2). To demonstrate the nature of residue(s) in paxillin that may be phosphorylated by HRG, we performed two-dimensional phosphoamino acid analysis. Results in Figure 3B demonstrate that HRG stimulated phosphorylation of paxillin, predominantly on serine residues. Phosphoamino acid analysis also showed a signi®cant HRG stimulation of paxillin phosphorylation on serine residues, and there was only a modest increase in tyrosine phosphorylation. The HRG induced phosphorylation of paxillin on serine residues and mobility shift was sensitive to serine/threonine phosphatase PP2B but not to protein tyrosine phosphatase PTP1 ( Figure 3C ). In brief, in contrast to earlier studies showing increased tyrosine phosphorylation of paxillin by other polypeptide factors, the present ®ndings demonstrated that HRG stimulates serine phosphorylation of paxillin.
Redistribution of paxillin from focal adhesions to cytoplasmic/perinuclear area by HRG Since HRG treatment of breast cancer cells leads to increased cell migration and invasiveness, we next explored the eect of HRG treatment on the possible redistribution of paxillin and its status in the focal adhesions using immuno-¯uorescence and confocal microscopy. To localize focal adhesions in MCF-7 cells, we used antibody against vinculin, a well known focal adhesion marker. Figure 4A shows that vinculin staining was presented in the characteristic dot-like structures representing focal adhesions. Paxillin staining of MCF-7 cells revealed the presence of paxillin in at least two distinct pools. One pool appeared to co-localize with the dot-like structures probably representing focal adhesions and the second paxillin pool appeared as a diused cytoplasmic staining, probably representing the cytoplasmic pool. Because both paxillin and vinculin antibodies (which work well in immuno-¯uorescence) used here were mAbs, we could not use these mAbs for colocalization of vinculin and paxillin. Since vinculin staining dots have been used to identify the focal adhesions (Arora et al., 1995; Chihara et al., 1997) we compared the vinculin and paxillin dots. The results indicated that both paxillin and vinculin were present in focal adhesions in control cells. To further con®rm that paxillin actually exists in focal adhesion of MCF-7 cells, we used another cytoskeletal protein, a-actinin for which commercial IgM2 mAb was available, and thus allowed us to co-stain with paxillin mAb. The pattern of a-actinin ( Figure 4C , green) staining in MCF-7 cells revealed its presence in the characteristic dot-like structures at the freeedges of cells as well as in ®laments. Co-staining of cells with paxillin and a-actinin revealed that paxillin was co-localized in the dot-like structures ( Figure 4C , indicated by yellow color). In brief, these results demonstrated that paxillin, at least, in part colocalizes in focal adhesions in MCF-7 cells.
Since the focal adhesion complexes are characterized by high levels of tyrosine phosphorylation, antiphosphotyrosine mAb PY20 has also been used to localize the focal contacts (Brown et al., 1998) . Since mAb PY20 does not stain ®laments like a-actinin, and in general exhibits very low background, we also used this antibody to localize focal adhesions. Cells were treated with or without HRG, and paxillin localization was visualized by double labeling using Abs against paxillin and phosphotyrosine. As illustrated in Figure 5 , MCF-7 cells were characterized by low levels of immunoreactivity for both tyrosine phosphorylation and paxillin, localized in the dot-like patches (focal contacts) at the cell periphery (arrows). In addition a second pool of paxillin was homogeneously distributed throughout the cytoplasm. A short-term (30 min) HRG stimulation of cells was accompanied by a signi®cant alteration in cell shape, with appearance of multiple dot-like patches positive to mAb PY20 corresponding to focal contacts. Interestingly, these focal contacts in HRG treated cells were in general devoid of paxillin. Instead, cytoplasmic paxillin was predominantly localized in the perinuclear cytoplasmic areas, and this pattern of paxillin redistribution was observed in almost all of the cell population ( Figure 5 ). This view is also supported by a recent ®nding by Mazaki et al. (1997) , demonstrating that a cytoplasmic pool of paxillin exists in the perinuclear area in NIH3T3 cells. Figure 6A ). Activation of PI-3K and p42/44 MAPK were sustained for up to 60 min while p38 MAPK was attenuated after 30 min, with peak activation at 10 min after treatment.
In order to delineate the signaling pathway(s) leading to serine phosphorylation of paxillin, we have employed three speci®c inhibitors Ly294002, PD98059 and SB203580 which speci®cally inhibit PI-3 kinase, p42/44 MAPK and p38 MAPK or anti-Phospho-p42/44 MAPK , and subsequently were reprobed with p38 MAPK or ERK mAbs. Cell lysates are also analysed for PI-3K activity. (B) Cells were cultured with or without HRG (30 ng/ml) for 30 min in the presence or absence of the indicated inhibitors. Cell lysates were blotted with anti-Paxillin mAb and the same blots were reprobed with anti-vinculin mAb. In addition, cell lysates were immunoprecipitated with anti-p38 MAPK antibody and subjected to immune-complex kinase assay using myelin basic protein as a substrate. (C) MCF-7 cells were metabolically labeled with 32 Porthophosphate and treated with HRG for 30 min in the presence of either SB203580 (20 mM) or LY294002 (40 mM). Cell lysates containing equal amount of protein was immunoprecipitated with paxillin mAb and developed by phosphoimager. Band intensity was measured by phosphoimager and after subtracting background phosphoimager units were used to plot the graph. (D) Cells were cultured with or without TGF-a (30 ng/ml) for indicated periods of time and lysed followed by immuno-blotting with paxillin, phospho p42/44 and phospho-p38 MAPK antibodies treatment of PI-3 kinase inhibitor Ly294002 failed to block the HRG-mediated mobility shift of paxillin to a signi®cant extent. At the moment, we do not know the reason for the small decrease in the incorporation. Since paxillin band still exhibited a mobility shift, we reasoned that Ly294002 may not block HRG mediated serine phosphorylation. The observed p38 MAPK -mediated stimulation of serine phosphorylation of paxillin was a speci®c eect of HRG, as there was no such eect of a closely related growth factor TGF-a on the mobility of paxillin protein band as well as activation of p38 MAPK in MCF-7 cells ( Figure 6D ). However, TGF-a treatment was very ecient in stimulating the activation of p42/44 MAPK ( Figure 6D , second panel). In brief, these results suggested that p38 MAPK pathway may be involved in HRG-mediated stimulation of serine phosphorylation of paxillin.
HRG induced cell shape changes and cell scattering are signi®cantly blocked by SB203580, a speci®c inhibitor of p38
MAPK
To examine the possible functional implication of p38 MAPK pathway during HRG-mediated redistribution of paxillin, we examined the in¯uence of p38 MAPK inhibition on the localization of paxillin by immunouorescence ( Figure 7) . Interestingly, pretreating of cells with the p38 MAPK inhibitor, and not the p42/44 MAPK inhibitor, blocked HRG-induced redistribution of paxillin. In p38 MAPK kinase inhibitor (SB203580) treated cells paxillin continue to remain in the focal points (see arrows in panel treated with SB203580, Figure 7 ). In the absence of HRG, there was no direct eect of treatment with either of these inhibitors on the distribution of paxillin. In order to investigate the eect of the p38 MAPK pathway on cell morphology during a longer (16 h) HRG treatment, MCF-7 cells were plated on a reconstituted basal membrane component Matrigel, treated with or without HRG in the presence or absence of p38 MAPK inhibitor SB203580, p42/44 MAPK inhibitor PD98059 and then stained with b-tubulin. This staining allowed us to determine alterations in cell shape even in conditions of serum starvation, where F-actin shows very low levels , and to distinguish between round cells that are in dierent stages of mitosis. As shown in Figure 8A , HRG treatment induced motile phenotypic changes in MCF-7 cells that were characterized by appearance of a bipolar cell shape and cell scattering. P38 MAPK inhibitor SB203580 pretreatment signi®cantly inhibited HRG mediated cell scattering. However, SB203580 treatment only partially inhibited HRG mediated cell morphology changes. p42/44 MAPK inhibitor PD98059 has no inhibitory eect on the HRG mediated cell scattering. As expected from the data in Figure 6D , there was no scattering eect of TGF-a in MCF-7 cells ( Figure 8A ). Quantitation of cell scattering demonstrated that about 80% of HRG-stimulated cells exhibited cell-scattering phenotype ( Figure 8B ). Cotreatment of cells with SB203580 and HRG significantly reduced the scattered cells to 30%. Cotreatment of cells with p42/p44 MAPK inhibitor has no eect on the HRG mediated cell scattering. These results support a possible role of p38 MAPK kinase pathway in HRG mediated cell scattering. 
Dominant negative p38
MAPK mutant signi®cantly blocked HRG induced paxillin serine phosphorylation and its redistribution from focal adhesions
The role of p38 MAPK pathway in the serine phosphorylation and redistribution of paxillin was also validated by using a Flag-tagged dominant negative p38 MAPK (P38AF) in which two activating phosphorylating sites of p38 MAPK were mutated with Alanine (A) and Phenylalanine (F) (Ludwig et al., 1998) . MCF-7 were transfected with either Flag-tagged vector or p38AF plasmid and treated with or without HRG. As illustrated in the Figure 9A MAPK kinase pathway in HRG-mediated serine phosphorylation of paxillin and its redistribution.
Discussion
Our present ®ndings demonstrate a role of p38 MAPK activation in HRG-induced increased phosphorylation of paxillin and in HRG induced scattering of breast cancer cells. In the past, a number of growth factors have been shown to concurrently induce tyrosine phosphorylation of paxillin and FAK in the focal points, and also modulate cell adhesion and spreading phenotypes of cells (Leventhal et al., 1997; Matsumoto et al., 1994) . In contrast to the earlier reports, we have now demonstrated, for the ®rst time, the potential involvement of serine phosphorylation of paxillin during HRG-induced cell shape changes. The migration of paxillin as a diuse band with slower mobility has been shown to be associated with serine/threonine phosphorylation (Turner et al., 1990) . Data from the literature suggest that paxillin can be phosphorylated on serine residues in response to cell adhesion to ®bronectin (Bellis et al., 1997) and vitronectin (De Nichilo and Yamada, 1996) . However, in both of these cases, paxillin was localized to focal adhesion, as opposed to HRG treatment which relocalizes paxillin to perinuclear areas.
The paxillin protein contains multiple serine phosphorylation sites and several motifs with potential roles in protein-protein interactions, including four LIM double zinc ®nger domains . Recently serine phosphorylation of paxillin LIM domains was shown to play an important role in localization of paxillin to focal adhesions (Brown et al., 1998) . In addition to serine phosphorylation, recruitment of paxillin to focal adhesions in growth factorstimulated cells also requires tyrosine phosphorylation (Abedi et al., 1995; Abedi and Zachary, 1997; Leventhal et al., 1997; Matsumoto et al., 1994; Hiregowdara et al., 1997) . In view of these observations, our ®nding that HRG stimulation of breast cancer cells leads to serine phosphorylation of paxillin as well as its redistribution from focal adhesions to perinuclear areas are novel, as these changes in paxillin protein may be closely linked to cytoskeletal reorganization leading to cell shape changes and cell scattering, two essential components of cell motility. The potential signi®cance of serine phosphorylation of paxillin in the disassembly of focal adhesion is also deduced from the observations that disorganization of the focal adhesions during mitosis is accompanied by serine phosphorylation of paxillin (Yamaguchi et al., 1997) .
In an attempt to reconcile our ®ndings with the existing information, we suggest that in addition to the formation of new focal adhesions, disassembly of paxillin from focal complexes may also play an equally important role during HRG-mediated increased cell motility by contributing to cell shape changes.
Another notable ®nding in this study was a potential role of p38 MAPK in mediating the serine phosphorylation and cell scattering function of HRG. The evidence that inhibition of p38 MAPK has the capacity to inhibit the biological eects of HRG on the redistribution of paxillin and cell scattering of breast cancer cells, is of special interest, as it strongly suggests that HRG primarily utilizes the p38 MAPK -dependent signal transduction pathway to transduce its signal(s) leading to paxillin phosphorylation and scattering. This hypothesis is further supported by our ®ndings that pretreatment of MCF-7 cells with inhibitors of PI-3 kinase and MAPK pathways, which are rapidly stimulated by HRG, did not in¯uence either the phosphorylation status of paxillin or its redistribution. However, PI-3 kinase has been shown to be essential during HRG-induced activation of PAK1 and actin reorganization , and also in PDGF-induced tyrosine phosphorylation of paxillin in Swiss 3T3 ®broblast cells (Abedi et al., 1995) .
Recently, HER2 transformed NIH3T3 cells have been shown to exhibit abnormalities in cytoskeleton structure. In this study, the paxillin was not tyrosine phosphorylated but demonstrated an increased association with FAK (Lo et al., 1999) . Results of this study demonstrate that HRG (1 nM) induces serine, but not tyrosine phosphorylation. Failure of activated HER2 or HRG to induce tyrosine phosphorylation of paxillin raises the possibility that serine modi®cation of paxillin may confer cancer cells an advantage in migration by interfering with the attachment to extracellular matrix, and this may involve blocking or sequestering signaling molecules or interfering with signal transduction from focal adhesions. Alternatively removal of paxillin from focal adhesion may have a role in dissociation of existing focal adhesions. Since HRG induces motility, dissolution of focal adhesions may contribute to motile phenotype induced by HRG.
At the moment, we do not know the mechanism by which p38
MAPK executes its profound stimulatory eects on phosphorylation and redistribution of paxillin in HRG treated cells. It is possible that paxillin may be directly or indirectly activated by p38 MAPK and/or by one or more of its downstream serine/threonine kinase(s (Cano and Mahadevan, 1995) . These kinases are activated by distinct upstream dual speci®city kinases (MAP kinase kinase or MKK). The p38 MAPK is activated by stress, in¯ammatory cytokines such as IL-1 and TNF (Cano and Mahadevan, 1995) , and HRG (this study). The p38 MAPK is activated by MKK3/ 6, and by MKK4 (also activates JNKs, known to be stimulated by HRG, ). Activated p38 MAPK phosphorylates and activates MAPK activated protein kinase-2 (MAPKAPK-2) (Rouse et al., 1994) , mitogen-and stress-activated protein kinase-1 (MSK1) (Deak et al., 1998) , and the transcription factors ATF2, Max and CREB.
In addition to the p38 MAPK -dependent pathway, data from the literature suggest that LIM2 and LIM3 domains of paxillin could serve as substrates for uncharacterized serine/threonine kinases (Brown et al., 1998) . However, mutations in serine residues in LIM domains had no phenotypic eect on paxillin localization to focal points (Brown et al., 1998) , and thus, are unlikely to be involved in the observed HRGmediated serine phosphorylation of paxillin as it was accompanied by a distinct redistribution from focal adhesions to perinuclear areas (Figure 2 ). In summary, regardless of the mechanism by which p38 MAPK controls activation of paxillin, our ®ndings have clearly demonstrated for the ®rst time a role of p38 MAPK -dependent signal transduction pathway(s) in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape changes and cell-scattering.
Materials and methods
Cell cultures and reagents
MCF-7 human breast cancer cells were maintained in DMEM-F12 (1 : 1) supplemented with 10% fetal calf serum. Antibodies against HER2 (#MS-325-P), PY20 (#MS445-P) Paxillin (#MS404-P) and recombinant heregulin beta-1 were purchased from Neomarkers Inc. Antibodies for FAK (#F2918), Vinculin (#V913) and Tubulin (#T4026), alphaactinin (#A-5044), anti IgM FITC (#F-9259) and acid phosphatase were from Sigma. Antibodies for phospho p42/ 44 (#9105S) and p38 MAPK (#9211S) were from the New England Biolabs. Flag polyclonal antibody was obtained from Santa Cruz (#SC-807G). Inhibitors Ly294002, SB203580 and PD98059 were purchased from Calbiochem. Protein tyrosine phosphatase 1B, Protein phosphatase 2B and anti-phosphotyrosine (4G10) were purchased from the Upstate Biotechnology.
Cell extracts, immunoblotting and immunoprecipitation
For preparation of cell extracts, cells were washed 36 with phosphate buered saline and lysed in buer (50 mM Tris-HCl, pH 7.5; 120 mM NaCl; 0.5% NP-40; 100 mM NaF; 200 mM NaVO 5 ; 1 mM PMSF; 10 mg/ml leupeptin; 10 mg/ml apotinin) for 15 min on ice. The lysates were centrifuged in an Eppendorf centrifuge at 48C for 15 min. Cell lysates containing equal amounts of protein were resolved on a 10% SDS-polyacrylamide gel, transferred to nitrocellulose, and probed with the appropriate antibodies, using an ECL method or alkaline phosphatase-based color reaction method (Bandyopadhyay et al., 1998) .
Phosphoamino acid analysis and phosphatase treatment MCF-7 cells were in vivo equilibrium labeled with 32 POrthophosphoric acid for 10 h and treated with HRG. Paxillin was immunoprecipitated with anti-paxillin antibodies. Paxillin band was excised from the gel hydrolyzed in 6 M HCl for 90 min and phosphoamino acid analysis was performed on two dimensional thin-layer chromatography as described (Kumar et al., 1991) . For phosphatase treatment, cells were treated with or without HRG for 30 min, immunoprecipitated with anti-paxillin antibodies. Equal amount of immunoprecipitate was washed three times with respective buers and treated with phosphatases in a ®nal volume of 30 ml. The following conditions were used for dephosphorylation. Acid phosphatase: 10 mM Tris Acetate, pH 5.5, 1 mM DTT, 10 min at 308C; PTP-IB, 25 mM Imidazole-HCl pH 7.0, 1 mg/ml BSA, 0.1% BME, 60 min at 308C; PP-1, 50 mM Tris, 1 mM DDT, 1 mM MnCl 2 , 0.1 unit/reaction, 30 min at 378C; PP2B, 40 mM HEPES pH 7.6, 40 mM NaCl, 0.5 mM MgCl 2 , 0.5 mM MnCl 2 , 1 mg/reaction 30 min at 378C.
Kinase assays
For assays determining activation of MAP Kinases equal amount of proteins were immunoblotted with antibodies which speci®cally recognize tyrosine phosphorylated activated kinases (NEB) according to manufacturer's protocol. PI-3 kinase assays were performed as described . In some experiments cells were treated with inhibitors of PI-3 kinase (Ly294002, 40 mM), p42/44 MAPK (PD98059, 40 mM) and p38 MAPK (SB203580, 20 mM) 30 min before HRG treatment. The p38 MAPK activity was determined by an in-vitro kinase assay using myelin basic protein (MBP) as a substrate.
Immuno-¯uorescence and cell morphology
For cell morphology, cells cultured on glass cover slips or in chamber slides (Falcon) were ®xed with methanol for 10 min at 7208C. For indirect immuno-¯uorescence, ®xed cells were washed two times with PBS, blocked by incubation with 10% normal goat serum (Sigma) in PBS for 1 h at ambient temperature. Cells were then allowed to react for 1 h at ambient temperature with mouse monoclonal antibody against paxillin, rabbit polyclonal antibody against PY20 aactinin or vinculin mAbs. For detection of Flag-tagged p38AF mutant or control Flag-vector transfected cells, we have used a rabbit polyclonal antibody raised against FLAG epitope (SC-807, Santa Cruz). After four washes with PBST cells were incubated with ALEXA-or FITC-conjugated, goat anti-mouse IgG, or TRITC-conjugated goat anti-rabbit IgG (Molecular Probes), all at a 1 : 100 dilution in 10% normal goat serum in PBS. For controls, cells were treated only with the secondary antibody, omitting the primary antibody, and no signals were detected in control untreated cells. Cells were viewed with an inverted Zeiss Axioplan¯uorescence microscope with a charged-coupled-device camera, using the IP-Lab Spectrum software and in some experiments slides were analysed by confocal microscopy.
Cell transfections
P38AF dominant negative mutant (Ludwig et al., 1998) and Flag tagged vector were transfected into MCF-7 cells using transfection reagent Fugene-6 as per manufacturer's protocol (Boehringer Mannheim). Twenty-four hours after transfection, cells were serum starved for a further 24 h, stimulated with HRG for 30 min and then cells were either lysed for Western analysis or stained with paxillin and Flag antibodies for immuno-¯uorescence analysis. Each experiment was repeated with three independent transfections and transfection eciency varied between 40 ± 50%.
Cell scattering assays
For cell-scattering assay, cover slips were coated with a thin layer of Matrigel before plating the cells. Cells were treated with or without HRG for 16 h in the presence or absence of inhibitors SB203580 (20 mM) or PD980599 (40 mM). Cells were washed and ®xed as described earlier and stained with b-tubulin monoclonal and visualized by confocal microscopy. For quantitation of cell scattering, cells in random seven ®elds were counted (the average number of cells per ®eld was between 80 and 90, corresponding to 206 magni®cation) and percentage of cells scattered from cell clusters are presented.
